🧐 ProPicks AI October update is out now! See which stocks made the listPick Stocks with AI

U.S. CDC recommends use of Novavax's COVID shot for adolescents

Published 08/22/2022, 11:43 AM
Updated 08/22/2022, 12:56 PM
© Reuters. FILE PHOTO: Vials with a sticker reading, "COVID-19 / Coronavirus vaccine / Injection only" and a medical syringe are seen in front of a displayed Novavax logo in this illustration taken October 31, 2020. REUTERS/Dado Ruvic/Illustration
PFE
-
NVAX
-
MRNA
-

(Reuters) - The U.S. Centers for Disease Control and Prevention (CDC) on Monday signed off on the use of Novavax (NASDAQ:NVAX) Inc's COVID-19 vaccine for adolescents aged 12 through 17.

The recommendation follows the U.S. Food and Drug Administration's authorization for the vaccine for the age group last week.

The protein-based vaccine received emergency use authorization in July for use among adults in the United States, with health officials hoping it would drive uptake among those skeptical of messenger RNA shots from Moderna (NASDAQ:MRNA) Inc and Pfizer Inc. (NYSE:PFE)

However, Novavax earlier this month halved its full-year revenue forecast, saying it does not expect further sales of its COVID-19 shot in the United States this year.

The company said it was late to the U.S. market and also pointed to softer demand in the face of a global vaccine supply glut.

© Reuters. FILE PHOTO: Vials with a sticker reading,

So far 11,990 Novavax vaccine doses have been administered in the United States, according to latest government data.

The vaccine, which has already been cleared in countries such as Japan and Australia for use among adolescents, has also been plagued by manufacturing snags, regulatory delays and sluggish uptake in key markets such as Europe.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.